Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Zivo Bioscience ( (ZIVO) ).
On July 8, 2025, Zivo Bioscience, Inc. issued a Bridge Promissory Note worth $250,000 and a warrant to purchase shares as part of a new convertible debt offering aimed at raising $2,000,000. This financial maneuver is designed to provide flexibility in financing, allowing conversion of debt to equity under certain conditions, which could impact the company’s capital structure and appeal to investors by offering potential equity participation.
Spark’s Take on ZIVO Stock
According to Spark, TipRanks’ AI Analyst, ZIVO is a Underperform.
Zivo Bioscience faces significant financial challenges, including negative equity and cash flow issues, which are the primary factors in its low score. Despite some technical indicators showing neutrality, the company’s negative valuation metrics further impact the score. Urgent financial restructuring is necessary for sustainability.
To see Spark’s full report on ZIVO stock, click here.
More about Zivo Bioscience
Zivo Bioscience, Inc. operates in the biotechnology industry, focusing on developing and commercializing health and wellness products derived from its proprietary algal culture technology.
Average Trading Volume: 1,012
Technical Sentiment Signal: Sell
Current Market Cap: $51.94M
For a thorough assessment of ZIVO stock, go to TipRanks’ Stock Analysis page.